Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01138085
Title Safety, Pharmacokinetics (PK) of AKT and MEK Combination
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

Advanced Solid Tumor

Therapies

Trametinib + Uprosertib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST